Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure
- 1 October 1987
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 114 (4), 805-813
- https://doi.org/10.1016/0002-8703(87)90791-5
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failureThe American Journal of Cardiology, 1986
- Epidemiology of congestive heart failureThe American Journal of Cardiology, 1985
- Cardiopulmonary exercise testing for evaluation of chronic cardiac failureThe American Journal of Cardiology, 1985
- Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failureJournal of the American College of Cardiology, 1984
- Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart FailureNew England Journal of Medicine, 1983
- Prognosis in severe heart failure: Relation to hemodynamic measurements and ventricular ectopic activityJournal of the American College of Cardiology, 1983
- The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.Circulation, 1983
- Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure.Circulation, 1982
- Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.Circulation, 1981
- Long-Term Vasodilator Therapy with Trimazosin in Chronic Cardiac FailureNew England Journal of Medicine, 1980